Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 8,250,000 shares, a growth of 5.4% from the January 15th total of 7,830,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is presently 5.5 days. Currently, 22.6% of the company’s stock are sold short.
Ginkgo Bioworks Stock Down 6.4 %
Shares of NYSE DNA opened at $13.79 on Wednesday. The firm’s 50-day moving average is $11.34. Ginkgo Bioworks has a 1-year low of $5.26 and a 1-year high of $64.40. The firm has a market capitalization of $792.36 million, a price-to-earnings ratio of -1.05 and a beta of 1.16.
Hedge Funds Weigh In On Ginkgo Bioworks
Institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. acquired a new position in shares of Ginkgo Bioworks during the fourth quarter valued at about $29,000. KBC Group NV acquired a new position in shares of Ginkgo Bioworks during the fourth quarter valued at about $31,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Ginkgo Bioworks in the 4th quarter worth about $46,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Ginkgo Bioworks in the 4th quarter worth about $116,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Ginkgo Bioworks in the 4th quarter worth about $144,000. Institutional investors and hedge funds own 78.63% of the company’s stock.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
- Five stocks we like better than Ginkgo Bioworks
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- There Are Different Types of Stock To Invest In
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- ESG Stocks, What Investors Should Know
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.